MERCK Kommanditgesellschaft auf Aktien
Market Cap
€45.3b
Last Updated
2020/07/01 21:29 UTC
Data Sources
Company Financials +
Executive Summary
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Solid track record average dividend payer.
Similar Companies
Share Price & News
How has MERCK Kommanditgesellschaft auf Aktien's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MRCK has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
3.9%
MRCK
-0.5%
AT Pharmaceuticals
1.6%
AT Market
1 Year Return
8.8%
MRCK
11.1%
AT Pharmaceuticals
-21.9%
AT Market
Return vs Industry: MRCK underperformed the Austrian Pharmaceuticals industry which returned 11.3% over the past year.
Return vs Market: MRCK exceeded the Austrian Market which returned -21.9% over the past year.
Shareholder returns
| MRCK | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.9% | -0.5% | 1.6% |
| 30 Day | 0.8% | 0.6% | -0.03% |
| 90 Day | 15.4% | 10.0% | 12.4% |
| 1 Year | 10.2%8.8% | 14.7%11.1% | -21.0%-21.9% |
| 3 Year | 3.9%-0.2% | 29.9%14.8% | -15.0%-21.4% |
| 5 Year | n/a | 34.2%11.0% | 20.1%5.0% |
Price Volatility Vs. Market
How volatile is MERCK Kommanditgesellschaft auf Aktien's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is MERCK Kommanditgesellschaft auf Aktien undervalued compared to its fair value and its price relative to the market?
26.1%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MRCK (€104) is trading below our estimate of fair value (€140.79)
Significantly Below Fair Value: MRCK is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MRCK is poor value based on its PE Ratio (29.2x) compared to the Pharmaceuticals industry average (24.4x).
PE vs Market: MRCK is poor value based on its PE Ratio (29.2x) compared to the Austrian market (10.8x).
Price to Earnings Growth Ratio
PEG Ratio: MRCK is poor value based on its PEG Ratio (2.2x)
Price to Book Ratio
PB vs Industry: MRCK is good value based on its PB Ratio (2.4x) compared to the XE Pharmaceuticals industry average (3.1x).
Next Steps
Future Growth
How is MERCK Kommanditgesellschaft auf Aktien forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
13.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRCK's forecast earnings growth (13.6% per year) is above the savings rate (0.5%).
Earnings vs Market: MRCK's earnings (13.6% per year) are forecast to grow slower than the Austrian market (22.8% per year).
High Growth Earnings: MRCK's earnings are forecast to grow, but not significantly.
Revenue vs Market: MRCK's revenue (4.9% per year) is forecast to grow faster than the Austrian market (3.5% per year).
High Growth Revenue: MRCK's revenue (4.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MRCK's Return on Equity is forecast to be low in 3 years time (12.4%).
Next Steps
Past Performance
How has MERCK Kommanditgesellschaft auf Aktien performed over the past 5 years?
2.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRCK has high quality earnings.
Growing Profit Margin: MRCK's current net profit margins (9.2%) are higher than last year (6.2%).
Past Earnings Growth Analysis
Earnings Trend: MRCK's earnings have grown by 2.2% per year over the past 5 years.
Accelerating Growth: MRCK's earnings growth over the past year (64.8%) exceeds its 5-year average (2.2% per year).
Earnings vs Industry: MRCK earnings growth over the past year (64.8%) exceeded the Pharmaceuticals industry 5.5%.
Return on Equity
High ROE: MRCK's Return on Equity (8.3%) is considered low.
Next Steps
Financial Health
How is MERCK Kommanditgesellschaft auf Aktien's financial position?
Financial Position Analysis
Short Term Liabilities: MRCK's short term assets (€10.0B) do not cover its short term liabilities (€10.8B).
Long Term Liabilities: MRCK's short term assets (€10.0B) do not cover its long term liabilities (€15.4B).
Debt to Equity History and Analysis
Debt Level: MRCK's debt to equity ratio (71%) is considered high.
Reducing Debt: MRCK's debt to equity ratio has increased from 57.3% to 71% over the past 5 years.
Debt Coverage: MRCK's debt is well covered by operating cash flow (21.8%).
Interest Coverage: MRCK's interest payments on its debt are well covered by EBIT (8.9x coverage).
Balance Sheet
Next Steps
Dividend
What is MERCK Kommanditgesellschaft auf Aktien current dividend yield, its reliability and sustainability?
1.25%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MRCK's dividend (1.25%) isn’t notable compared to the bottom 25% of dividend payers in the Austrian market (1.6%).
High Dividend: MRCK's dividend (1.25%) is low compared to the top 25% of dividend payers in the Austrian market (5.18%).
Stability and Growth of Payments
Stable Dividend: MRCK's dividends per share have been stable in the past 10 years.
Growing Dividend: MRCK's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (36.4%), MRCK's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: MRCK's dividends in 3 years are forecast to be well covered by earnings (20% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.8yrs
Average management tenure
CEO
Stefan Oschmann (63yo)
4.25yrs
Tenure
€9,823,000
Compensation
Dr. Stefan Oschmann has been the Chairman of Executive Board and Chief Executive Officer of Merck KGaA since April 30, 2016. Dr. Oschmann has been a Member of Executive Board for Merck KGaA since January 1 ...
CEO Compensation Analysis
Compensation vs Market: Stefan's total compensation ($USD11.06M) is above average for companies of similar size in the Austrian market ($USD3.99M).
Compensation vs Earnings: Stefan's compensation has increased by more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of Executive Board & CEO | 4.25yrs | €9.82m | no data | |
| CFO & Member of Executive Board | 6.17yrs | €4.56m | no data | |
| CEO of Performance Materials & Member of the Executive Board | 9.25yrs | €4.95m | no data | |
| CEO of Life Science & Member of Executive Board | 4.25yrs | €5.45m | no data | |
| CEO of Healthcare & Member of the Executive Board | 5.5yrs | €5.80m | no data | |
| Head of Global Accounting | 6.67yrs | no data | no data | |
| Chief Information Officer | 2.33yrs | no data | no data | |
| Head of Investor Relations | 7.5yrs | no data | no data | |
| Group General Counsel and Head of Group Legal & Compliance | 6.25yrs | no data | no data | |
| Chief Compliance Officer | 1yr | no data | no data |
5.8yrs
Average Tenure
52yo
Average Age
Experienced Management: MRCK's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Member of Supervisory Board | 12.33yrs | €50.00k | no data | |
| Non-Executive Director | 3.58yrs | no data | no data | |
| Independent Chairman of Supervisory Board | 6.17yrs | €97.75k | no data | |
| Independent Member of Supervisory Board | 1.25yrs | €35.19k | no data | |
| Independent Member of Supervisory Board | 6.17yrs | €50.00k | no data | |
| Independent Member of Supervisory Board | 6.17yrs | €50.75k | no data | |
| Independent Member of Supervisory Board | 6.17yrs | €50.75k | no data | |
| Member of Supervisory Board | 0.17yr | €15.69k | no data | |
| Independent Member of Supervisory Board | 1.25yrs | €35.19k | no data | |
| Independent Member of Supervisory Board | 1.25yrs | €35.19k | no data |
4.9yrs
Average Tenure
58.5yo
Average Age
Experienced Board: MRCK's board of directors are considered experienced (4.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
MERCK Kommanditgesellschaft auf Aktien's company bio, employee growth, exchange listings and data sources
Key Information
- Name: MERCK Kommanditgesellschaft auf Aktien
- Ticker: MRCK
- Exchange: WBAG
- Founded: 1668
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €45.347b
- Shares outstanding: 434.78m
- Website: https://www.merckgroup.com
Number of Employees
Location
- MERCK Kommanditgesellschaft auf Aktien
- Frankfurter Strasse 250
- Darmstadt
- Hessen
- 64293
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MKGA.F | OTCPK (Pink Sheets LLC) | Yes | Bearer Shares | US | USD | Oct 1995 |
| MRK | DB (Deutsche Boerse AG) | Yes | Bearer Shares | DE | EUR | Oct 1995 |
| MRK | XTRA (XETRA Trading Platform) | Yes | Bearer Shares | DE | EUR | Oct 1995 |
| 0O14 | LSE (London Stock Exchange) | Yes | Bearer Shares | GB | EUR | Oct 1995 |
| MRKD | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Bearer Shares | GB | EUR | Oct 1995 |
| MRCK | WBAG (Wiener Boerse AG) | Yes | Bearer Shares | AT | EUR | Oct 1995 |
| MER | SWX (SIX Swiss Exchange) | Yes | Bearer Shares | CH | CHF | Oct 1995 |
| MRK | BIT (Borsa Italiana) | Yes | Bearer Shares | IT | EUR | Oct 1995 |
| MKKG.Y | OTCPK (Pink Sheets LLC) | SPON ADR EACH REPR 0.2 ORD SHS | US | USD | Sep 2007 | |
| MRKC | BST (Boerse-Stuttgart) | SPON ADR EACH REPR 0.2 ORD SHS | DE | EUR | Sep 2007 |
Biography
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer or multiple sclerosis, infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as carcinoma of the head and neck; prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for the research and applied laboratory applications, as well as for formulating, purifying, manufacturing, and quality-assuring drug therapies of chemical and biological origin; and specialty chemicals, such as liquid crystals and OLED materials for use in displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Intrexon Corporation and Avillion LLP; and collaboration with F-star Delta Ltd. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/01 21:29 |
| End of Day Share Price | 2020/06/29 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.